G D Demetri

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group
    G D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:3412-25. 1998
  2. ncbi Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy
    G D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 84:31-7. 2001
  3. ncbi Targeted approaches for the treatment of thrombocytopenia
    G D Demetri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
    Oncologist 6:15-23. 2001

Detail Information

Publications3

  1. ncbi Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group
    G D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:3412-25. 1998
    ..To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response...
  2. ncbi Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy
    G D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 84:31-7. 2001
    ..With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer...
  3. ncbi Targeted approaches for the treatment of thrombocytopenia
    G D Demetri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
    Oncologist 6:15-23. 2001
    ..As a potent stimulator of platelet production, rHuTPO has the potential to reduce the need for platelet transfusions and their attendant complications...